Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Gastrointestinal 1

Conditions

Sarcoma 1 Neoplasms 1 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

Oxaliplatin 16 Irinotecan 12 Fluorouracil 12 Leucovorin 10 Bevacizumab 8 pembrolizumab 7 Cetuximab 7 Capecitabine 7 Nivolumab 5 Gemcitabine 5 Cyclophosphamide 5 fludarabine 4 aldesleukin 4 Panitumumab 4 Folfox protocol 4 oblimersen 3 Interleukin-2 3 selpercatinib 2 poly ICLC 2 labetuzumab 2 dehydroftorafur 2 conatumumab 2 cemiplimab 2 bintrafusp alfa protein, human 2 Tomography, X-Ray Computed 2 Specimen Handling 2 Receptor Protein-Tyrosine Kinases 2 Radiotherapy 2 Levoleucovorin 2 Injections 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Colonic Neoplasms × bexmarilimab × Clear all

NCT05104905 2022-05-11

RENACOL

Faron Pharmaceuticals Ltd

Phase 1/2 Withdrawn

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡